BioSyntech presents BST-CarGel(R) Cartilage Repair trial design at the 2009 World Congress on Osteoarthritis in Montreal



    LAVAL, QC, Sept. 9 /CNW/ - BioSyntech, Inc. (TSX: BSY), a biotechnology
company developing biotherapeutic thermogels for regenerative medicine, today
announced it will present a poster entitled "Challenges in Designing
Randomized Clinical Trials for Cartilage Repair: The BST-CarGel(R) Experience"
at the 2009 World Congress on Osteoarthritis held from September 10-13 in
Montreal, Canada. The Company recently reported statistically significant
evidence of improved repair tissue quality due to BST-CarGel(R) treatment
during analyses of tissues biopsied from the knees of 22 patients who
completed their 12 month follow-up in the BST-CarGel(R) randomized pivotal
clinical trial.
    "Designing a trial capable of validating the ability of our product to
regenerate high quality cartilage presented many complex challenges that
BioSyntech had to overcome, highlighting the considerable expertise of our
team," said Ms. Jeanne Bertonis, Chief Executive Officer for BioSyntech. "This
conference is also the ideal venue to continue our ongoing discussions with
potential strategic partners and drive anticipation for the final clinical
results from our pivotal trial, which should be available in the summer of
2010."
    Poster No. 32 entitled "Challenges in Designing Randomized Clinical
Trials for Cartilage Repair: The BST-CarGel(R) Experience" will be presented
between 3:30-5:00PM ET on Friday, September 11th and Saturday, September 12th
at the Hilton Montreal Bonaventure in Montreal. Additional information on the
2009 World Congress on Osteoarthritis can be found at
http://www.oarsi.org/meetings/09Congress.

    About BioSyntech

    BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. For
additional information, visit www.biosyntech.com.

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at www.sedar.com. These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.

    %SEDAR: 00020217EF




For further information:

For further information: Casey Gurfinkel, The Equicom Group, (416)
815-0700 x283, cgurfinkel@equicomgroup.com

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890